A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer

Autor:	George Agyapong, Debashish Misra, C Douglas Taylor, Jun Liu, David Hirsh
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty lcsh:Medicine Case Report Case Reports 030204 cardiovascular system & hematology paraneoplastic syndrome 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Cholestasis Internal medicine Rare case Medicine Enzalutamide lcsh:R5-920 adverse drug reactions enzalutamide business.industry lcsh:R General Medicine prostate cancer medicine.disease humanities chemistry 030220 oncology & carcinogenesis Liver dysfunction lcsh:Medicine (General) cholestasis business
Zdroj:	Clinical Case Reports Clinical Case Reports, Vol 7, Iss 11, Pp 2068-2073 (2019)
ISSN:	2050-0904
DOI:	10.1002/ccr3.2427
Popis:	Current safety data affirms enzalutamide does not cause clinically significant liver dysfunction that warrant therapy cessation. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or PnC. We report a case of paraneoplastic cholestasis (PnC) coinciding with enzalutamide initiation and masquerading as an enzalutamide‐related adverse event. Current safety data affirms that enzalutamide does not cause clinically significant liver dysfunction. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or PnC.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327bd6c1e674f5711a3bf864cd916610 https://doi.org/10.1002/ccr3.2427 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.